Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9310MR)

This product GTTS-WQ9310MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9310MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15596MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ8643MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ1590MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ7060MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ12859MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ6056MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ10535MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ7419MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW